We have several research projects which have been completed with fruitful results.@We will continuously support these projects in aspect of research funds and commercialization of those results.
- Development of a non-invasive drug delivery system using claudin modulator
-
- Project leader Masuo KONDOH, Ph.D.(Associate Professor, Graduate school of Parmaceutical Sciences, Osaka University)
- 2009-2010
- Dr. Kondoh has found that derivatives of C-terminal fragment of Clostridium perfringens enterotoxin
(C-CPE) enhanced the nasal and pulmonary absorption of a biologics. - Identification and development of a novel L-Ser analog as a novel inhibitor of osteoclastogenesis
and a therapeutic tool for bone destruction -
- Project leader Tatsuo TAKEYA, Ph.D.(ProfessorCGraduate School of Biological SciencesC Nara Institute of Science and Technology)
- 2009-2010
- Dr. Takeya has found that a L-serine analogue showed therapeutic and prophylactic activities in osteoporosis and also preventive effects on inflammation and destruction of bone in rheumatoid arthritis.
- Drug Development for Myelodysplastic Syndrome (MDS)
-
- Project leader Nobuo KATO, Ph.D.(ProfessorCThe Institute of Scientific and Industrial Research, Osaka University)
- 2009-2010
- Dr. Kato has achieved a technology transfer to a pharmaceutical company and the company is producing MBR-108 under GMP for the clinical trials.
- Post-antibody: Generation of Structured Binding Peptides by One-cell-picking Robotic System of Yeast-displayed Libraries
-
- Project leader Ikuo FUJII, Ph.D.(Professor, Graduate School of Science, Osaka Prefecture University)
- 2009-2010
- Dr. Fujii has developed a screening method for useful micro-antibodies displayed on the surface of yeast cells and showed that micro-antibodies against TNF-ż suppressed the TNF-induced necrosis of
L-929 cells. - Development of a new screening system for OA drug discovery using human stem cells and novel three dimensional cultured tissue
-
- Project leader Ken NAKATA (Associate Professor, Department of Orthopaedics, Osaka University Graduate School of Medicine)
- 2007-2009
- Dr. Nakata has developed a novel ex-vivo system to discover new drugs for osteoarthritis, which contains a cyclic load stimulator and chondrocytes cultured in new collagen scaffolds.
- A new biomarker of papillary thyroid carcinoma (PTC) :Development of measuring methods and its use for a new therapy of PTC
-
- Project leader Yukiko NAKATA (Assistant Professor, Department of Laboratory Medicine, Osaka University Graduate School of Medicne)
- 2008-2009
- Dr. Nakata and her colleagues are developing new biomarkers of papillary thyroid carcinoma to predict the prognosis of the carcinoma.
- Tetraspanins CD9/CD81 double-knockout mouse as a novel animal model for systemic COPD
-
- Project leader Isao TACHIBANA (Associate Professor, Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine)
- 2007-2009
- Dr. Tachibana has found that mice doubly deficient in CD9 and CD81 can be a model of chronic obstructive pulmonary disease (COPD) and that increase in CD9/CD81 expression can be effective to treat COPD.
- Development of therapeutic vaccine for hepatitis C capable of eliminating HCV from infected hepatocytes
-
- Project leader Yoshiharu Matsuura (Professor, Research Institute for Microbial Diseases, Osaka University)
- 2007-2009
- Dr. Matsuura has found that VAP-C, PA28γ, and TLR2/CD44/MyD88-dependent signal pathway can be candidates of a target for drug discovery in Hepatitis C.
- Research and development of highly comprehensive intelligent human care systems
-
- Project leader Luo Zhi-wei (Professor of Graduate School of Engineering, Kobe University)
- 2007-2009
- Dr. Luo has developed a new machine for monitoring sense of equilibrium in aged persons using technologies of robotics . The machine could help to protect aged persons from accidental fall to the ground.
- Development of new adenovirus vectors which can avoid the generation of the replication-competent adenovirus
-
- Project leader Hiroyuki MIZUGUCHI (Project leader, Laboratory of Gene Transfer and Regulation, National Institute of Biomedical Innovation)
- 2007-2008
- Dr. Mizuguchi has developed a novel adenovirus vector which never generates replication-competent adenovirus through 16 passages.
- Novel Metabolic Stem Cell (MSC) based treatment system against the Metabolic Syndrome
- Project leader Kazuhisa MAEDA (Department of Metabolic Medicine, Graduate School of Medicine, Osaka University)
- 2007-2008
- Dr. Maeda and his colleagues are developing assay systems of adiponectin to use in personalized therapy of life-style diseases and in evaluation of invasive stress upon operation.
- Development of Innovative Therapeutic Strategy Based on New Principle for Myocardial Infarction
-
- Project leader Tatsuya SAWAMURA (Director, Department of Vascular Physiology, National Cardiovascular Center Research Institute)
- 2007-2008
- Dr. Sawamura has proved that anti-LOX-1 antibody suppressed the size of myocardial infarction in a rabbit model and activation of platelets as well.
- Development of a new drug for congestive heart failure by anti-periostin neutralizing antibody
-
- Project leader Yoshiaki TANIYAMA (Associate Professor, Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine)
- 2007-2008
- Dr. Taniyama has shown that neutralizing periostin-1 antibody can improve heart function in chronic heart failure by administration during acute myocardial infarction in a rat model.
